955 reports of this reaction
2.1% of all PIPERACILLIN SODIUM,TAZOBACTAM SODIUM reports
#7 most reported adverse reaction
THROMBOCYTOPENIA is the #7 most commonly reported adverse reaction for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 955 FDA adverse event reports linking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM to THROMBOCYTOPENIA. This represents approximately 2.1% of all 44,977 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 955 FDA reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.1% of all adverse event reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, making it a notable side effect.
If you experience thrombocytopenia while taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.